For the quarter ending 2026-03-31, NAUT has $177,779K in assets. $33,364K in debts. $14,626K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 14,626 | 12,388 | 23,875 | 34,457 |
| Short-term investments | 81,243 | 91,018 | 107,552 | 113,416 |
| Prepaid expenses and other current assets | 2,963 | 2,557 | 2,898 | 2,852 |
| Total current assets | 98,832 | 105,963 | 134,325 | 150,725 |
| Property and equipment, net | 3,635 | 3,457 | 3,624 | 3,728 |
| Operating lease right-of-use assets | 26,631 | 27,773 | 24,727 | 25,920 |
| Long-term investments | 47,505 | 52,739 | 37,059 | 31,636 |
| Other long-term assets | 1,176 | 1,180 | 1,180 | 1,180 |
| Total assets | 177,779 | 191,112 | 200,915 | 213,189 |
| Accounts payable | 1,186 | 943 | 893 | 974 |
| Accrued expenses and other liabilities | 3,305 | 3,177 | 3,880 | 2,938 |
| Current portion of operating lease liabilities | 3,852 | 3,832 | 4,209 | 4,225 |
| Total current liabilities | 8,343 | 7,952 | 8,982 | 8,137 |
| Operating lease liabilities, net of current portion | 25,021 | 26,187 | 22,794 | 23,958 |
| Total liabilities | 33,364 | 34,139 | 31,776 | 32,095 |
| Common stock, 0.0001 par value, 1,000,000,000 shares authorized as of march31, 2026 and december31, 2025 127,070,480 and 126,469,610 shares issued and outstanding as of march31, 2026 and december31, 2025, respectively | 13 | 13 | 13 | 13 |
| Additional paid-in capital | 491,210 | 488,737 | 487,165 | 485,669 |
| Accumulated other comprehensive income (loss) | -91 | 243 | 200 | 77 |
| Accumulated deficit | -346,717 | -332,020 | -318,239 | -304,665 |
| Total stockholders equity | 144,415 | 156,973 | 169,139 | 181,094 |
| Total liabilities and stockholders equity | 177,779 | 191,112 | 200,915 | 213,189 |
Nautilus Biotechnology, Inc. (NAUT)
Nautilus Biotechnology, Inc. (NAUT)